secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMPEL PHARMACEUTICALS INC (—)
CIK:        0001445499
Form:       8-K
Filed at:   2023-10-04T23:59:59+00:00
Accession:  0000950170-23-051979
Event type: debt
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 2.03, 3.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Impel Pharma enters amended credit deal, draws $2.5M, faces Nasdaq delisting risk
--------------------------------------------------------------------------------

- Amended credit agreement waives defaults, permits additional $2.5M tranche B term loan draw; 75% funded Oct 2, remainder Oct 5.
- Nasdaq warns of delisting as stock closed below $1 for 30 days; company has until March 26, 2024 to regain compliance.
- Company required to use best efforts to raise ≥$5M equity by Oct 31, 2023; 50% of excess proceeds must repay tranche B loans.
- Must appoint one independent director acceptable to lenders by Oct 16, 2023; director to serve on committees including restructuring.
- Issued 445,293 warrants on Oct 2 and 148,431 warrants expected Oct 5 in connection with the term loan draw.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445499/000095017023051979/0000950170-23-051979-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445499/000095017023051979/impl-20230928.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-051979

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer